143 related articles for article (PubMed ID: 11022712)
21. Noninfective cutaneous granuloma with leuprorelin acetate--reality or myth.
Dangle P; Palit V; Sundaram SK; Weston P
Urology; 2007 Apr; 69(4):779.e5-6. PubMed ID: 17445679
[TBL] [Abstract][Full Text] [Related]
22. [Goserelin acetate depot, LH-RH agonist; its properties and therapeutic effects in prostate cancer].
Koga H; Naito S
Nihon Rinsho; 2000 Jul; 58 Suppl():186-90. PubMed ID: 11022711
[No Abstract] [Full Text] [Related]
23. [Time to normalization of testosterone after withdrawal of long time LH-RH agonist therapy in prostate cancer].
Kaku H; Tsushima T; Nasu Y; Kumon H
Nihon Rinsho; 2002 Dec; 60 Suppl 11():182-7. PubMed ID: 12599568
[No Abstract] [Full Text] [Related]
24. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations.
Goto R; Uda A; Hiroi S; Iwasaki K; Takashima K; Oya M
J Med Econ; 2017 Nov; 20(11):1155-1162. PubMed ID: 28758810
[TBL] [Abstract][Full Text] [Related]
25. Clinical pharmacokinetics of depot leuprorelin.
Periti P; Mazzei T; Mini E
Clin Pharmacokinet; 2002; 41(7):485-504. PubMed ID: 12083977
[TBL] [Abstract][Full Text] [Related]
26. Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment.
Herranz Amo F
Arch Esp Urol; 2010 May; 63(4):275-81. PubMed ID: 20508303
[TBL] [Abstract][Full Text] [Related]
27. [Granulomas induced by injections of leuprorelin acetate (Enantone®)].
Bruneu-Avierinos Y; Monestier S; Tasei AM; Gaudy-Marqueste C; Grob JJ; Richard MA
Ann Dermatol Venereol; 2011 Jan; 138(1):35-7. PubMed ID: 21276459
[TBL] [Abstract][Full Text] [Related]
28. [Surgical management of inflammatory granuloma which developed following subcutaneous injection of leuprorelin acetate: a case report].
Oida T; Shichiri Y; Takao N; Kanno T; Kanamaru H
Hinyokika Kiyo; 2005 Jul; 51(7):487-9. PubMed ID: 16119817
[TBL] [Abstract][Full Text] [Related]
29. Gonadotropin-releasing hormone agonist failure in a man with prostate cancer.
Smith MR; McGovern FJ
J Urol; 2001 Jul; 166(1):211. PubMed ID: 11435862
[No Abstract] [Full Text] [Related]
30. Comparison of tolerability and adverse events following treatment with two GnRH agonists in patients with advanced prostate cancer.
Shore ND; Sieber P; Schimke L; Perzin A; Olsen S
Urol Nurs; 2013; 33(5):236-44, 248. PubMed ID: 24354113
[TBL] [Abstract][Full Text] [Related]
31. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics.
Tombal B; Miller K; Boccon-Gibod L; Schröder F; Shore N; Crawford ED; Moul J; Jensen JK; Kold Olesen T; Persson BE
Eur Urol; 2010 May; 57(5):836-42. PubMed ID: 19962227
[TBL] [Abstract][Full Text] [Related]
32. Safety and clinical efficacy of a new 6-month depot formulation of leuprorelin acetate in patients with prostate cancer in Europe.
Tunn UW; Wiedey K
Prostate Cancer Prostatic Dis; 2009; 12(1):83-7. PubMed ID: 19030021
[TBL] [Abstract][Full Text] [Related]
33. Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer.
Wechsel HW; Zerbib M; Pagano F; Coptcoat MJ
Eur Urol; 1996; 30 Suppl 1():7-14; discussion 19-21. PubMed ID: 8977984
[TBL] [Abstract][Full Text] [Related]
34. Anaphylaxis to leuprolide acetate depot injection during treatment for prostate cancer.
Grant JP; Levinson AW
Clin Genitourin Cancer; 2007 Mar; 5(4):284-6. PubMed ID: 17553209
[TBL] [Abstract][Full Text] [Related]
35. A review of the pharmacokinetic and pharmacological properties of a once-yearly administered histrelin acetate implant in the treatment of prostate cancer.
Schlegel P
BJU Int; 2009 Mar; 103 Suppl 2():7-13. PubMed ID: 19228147
[No Abstract] [Full Text] [Related]
36. Clinical study results of the new formulation leuprorelin acetate three-month depot for the treatment of advanced prostate carcinoma.
Fornara P; Jocham D
Urol Int; 1996; 56 Suppl 1():18-22. PubMed ID: 8776813
[TBL] [Abstract][Full Text] [Related]
37. Injection-site granulomas due to the administration of leuprorelin acetate for the treatment of prostatic cancer.
Shiota M; Tokuda N; Kanou T; Yamasaki H
Fukuoka Igaku Zasshi; 2007 Jul; 98(7):301-4. PubMed ID: 17710895
[TBL] [Abstract][Full Text] [Related]
38. A morphological study of granulomas induced by subcutaneous injection of leuprorelin acetate.
Watanabe T; Yamada N; Yoshida Y; Yamamoto O
J Cutan Pathol; 2009 Dec; 36(12):1299-302. PubMed ID: 19469875
[TBL] [Abstract][Full Text] [Related]
39. Does needle size matter? Patient experience of luteinising hormone-releasing hormone analogue injection.
Montgomery BS; Borwell JP; Higgins DM
Prostate Cancer Prostatic Dis; 2005; 8(1):66-8. PubMed ID: 15700050
[TBL] [Abstract][Full Text] [Related]
40. Expert opinion on 6-monthly luteinizing hormone-releasing hormone agonist treatment with the single-sphere depot system for prostate cancer.
Schulman C; Alcaraz A; Berges R; Montorsi F; Teillac P; Tombal B
BJU Int; 2007 Jul; 100 Suppl 1():1-5. PubMed ID: 17593201
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
